FDA Approves Wegovy to Lower Risk for CVD Events in Patients With Obesity

FRIDAY, March 8, 2024 -- The U.S. Food and Drug Administration has approved Wegovy (semaglutide) for the prevention of myocardial infarction, stroke, and cardiovascular death in patients with obesity or overweight. In one multinational study...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news